Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
Western inventors have identified a group of 12 differentially expressed proteins in Preeclampsia (PE) patients using a state-of-art proteomics based approach. More
The University of Edinburgh has discovered a binding site for zinc in human albumin. More
VEGF111, a novel naturally occurring isoform of human VEGF-A, was recently cloned. VEGF111 is active in terms of activation of VEGF receptors, induction of endothelial cells multiplication and stimulation of vascularisation in vitro and in vivo. As r More
A novel PARG-like enzyme, ARH3, that appears to function in two important signaling pathways, serving to regulate both poly-ADP-ribose and O-acetyl-ADP-ribose levels. More
New composition for the prevention/treatment of Atherosclerosis More
Compositions and methods which employ a combination of monoclonal antibodies which bind to HGF and prevent it from binding to its receptor met in a manner that HGF/met signaling is neutralized More
Methods for identifying a subject at increased risk for developing AMD by determining the presence of protective genotypes at either the BF/C2 locus and at the CFH locus. More
A vector DNA that expresses the luciferase gene under the influence of a hypoxia inducible promoter sequence from the nitric oxide synthase gene has been used to transform various human tumor cell lines More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Angiogenesis
- Atherosclerosis
- Hypertension
- Hypotension
- Ischemia
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us